Idea Award – HT9425-23-MRP-IA
- up to USD$500,000 over 3 years
- Pre-proposals due 10 July 2023
- Supports new ideas that represent innovative, high-risk/high-gain approaches to melanoma research that are beyond an incremental advancement.
- Emphasis on innovation and impact.
- PIs new to the melanoma field are encouraged
- preliminary data discouraged
- clinical trials not allowed
- must address at least one MRP focus area
Melanoma Academy Scholar Award – HT9425-23-MRP-MASA
- up to USD$550,000 over 3 years
- letters of intent due 31 August 2023
- Supports the addition of new Scholars to the unique, interactive virtual Melanoma Academy that provides intensive mentoring, national networking, collaborations, and a peer group for early-career melanoma investigators.
- must be within 7 years of first faculty-level appointment
- Requires a Career Guide who is an experienced melanoma researcher with melanoma cancer funding, does not have to be a the same insititution
- preliminary data not required
- clinical trials not allowed
- must address at least one MRP focus area
Mid-Career Accelerator Award – HT9425-23-MRP-MCAA
- up to USD$725,000 over 3 years
- letters of intent due 31 August 2023
- Supports mid-career researchers conducting impactful melanoma research.
- must be Assistant or Assoc Prof (or equivalent) at least 7 years from first faculty-level appointment. must show evidence of at least one peer-reviewed source of external funding
- preliminary data relevant to melanoma required
- clinical trials not allowed
- must address at least one MRP focus area
Team Science Award – HT9425-23-MRP-TSA
- up to USD$1.25M over 3 years
- letters of intent due 31 August 2023
- Supports new or existing partnerships to address a research problem or question in a manner that would be unachievable through separate efforts.
- At least two and up to three Investigators must partner in one overarching
multidisciplinary research study. Independent investigators must be at level of Assistant Professor (or equivalent) or above - Inclusion of at least one military, US Department of Veterans Affairs, or ECR or is encouraged. Postdoctoral fellows are not eligible to be Initiating nor Partnering PIs.
- Intended to fund a broad range of studies including, but not limited to:
- Correlative studies that associated with an open/ongoing or completed clinical trial
- Research involving analysis of large and/or complex melanoma datasets
- Projects focusing on bioengineering approaches to address diagnostics, high risk markers, dormancy, and/or metastasis
- Research seeking to better understand and/or reduce inequities and disparities that impact melanoma patients and/or caregivers.
- Emphasis on synergy, multidisciplinary research, and impact.
- Applicants are encouraged but not required to collaborate with the melanoma community
- Preliminary data required
- clinical trials not allowed
- must address at least one MRP focus area
Focused Program Award – Rare Melanomas – HT9425-23-MRP-FPA-RM
- up to USD$2M over 4 years
- letters of intent due 31 August 2023
- Supports a synergistic, multidisciplinary research program of at least two but not more than three distinct but complementary projects addressing an overarching question relevant to rare melanomas.
- Applications may propose projects across the entire research spectrum (biology, etiology, prevention, diagnosis and detection, prognosis, treatment, and quality of life) and must address a critical unmet need relevant to rare melanomas (uveal, acral, mucosal, pediatric etc).
- Individual research projects may range from exploratory, hypothesis-developing studies through clinical trials
- Applicants are encouraged, but not required, to collaborate with the rare melanoma community
- clinical trials allowed
MRP Focus Areas
Prevention
- Identify and understand risk factors and biomarker determinants for melanoma, including rare subtypes.
- Develop prediction and surveillance tools for distinguishing patient populations and/or early tumors at risk for second primary, recurrence, metastasis, and/or treatment toxicity.
- Develop new tools for the detection of melanoma, which includes easily accessible technology (beyond the dermoscope) for primary care physicians, dermatologists, oncologists, and/or pathologists.
- Understand how precursor lesions evolve, and/or how environmental/endogenous factors influence melanomagenesis and/or early dissemination.
- Identify how the tumor microenvironment and/or microbiome impacts tumor initiation, response to therapy, progression, recurrence, and/or dormancy.
- Delineate the cellular and/or molecular mechanisms that influence metastatic spread (eg site-specific adaptations), recurrence, and/or dormancy.
- Develop new preclinical models of melanomagenesis, early dissemination, and progression that more faithfully represent the disease progression observed in humans.
Rare Melanoma
- Address unmet needs across the entire cancer research spectrum (biology, etiology, prevention, early diagnosis and detection, prognosis, treatment, and survivorship) for rare melanomas
Survivorship
- Address the physical and psychological impacts of a melanoma diagnosis, symptom trajectories, adverse effects of treatment, and other outcomes that affect individuals with melanoma and their family members.
Read more
Supporting documents
Refence Table of Award Mechanisms: 23mrpreftable
Idea Award: HT9425-23-MRP-IA-GG
Melanoma Academy Scholar Award: HT9425-23-MRP-MASA-GG
Mid-Career Accelerator Award:HT9425-23-MRP-MCAA-GG
Team Science Award: HT9425-23-MRP-TSA-GG
Focused Program Award – HT9425-23-MRP-FPA-RM-GG